Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The "UPK3BL-RASA4 readthrough" (ENSG00000205236) is a predicted gene fusion transcript resulting from a readthrough event between the adjacent UPK3BL and RASA4 genes on chromosome 7. Readthrough transcripts generally arise from transcription extending beyond the normal termination site of one gene into a neighboring gene. These transcripts are often annotated by automated genome annotation projects but rarely encode functional or physiologically relevant proteins, and there is no evidence in the published literature supporting a biological function or disease relevance for this specific readthrough. The component genes have known functions: RASA4 encodes a Ras GTPase-activating protein involved in signal transduction pathways, while UPK3BL is a poorly characterized gene of the uroplakin family. However, the fused readthrough product itself is not established as a functional protein, receptor, or therapeutic target. These types of predicted or computational transcripts are generally excluded from lists of valid molecular drug targets.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on UPK3BL-RASA4 readthrough transcript (ENSG00000205236).